arrow
G

Giuseppe Ronzitti

Université Paris Saclay
H指数:31
被引数:4,404

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

S-Nitrosylation of glycogen phosphorylase regulates nuclear glycogenolysis and is impaired in metabolic liver disorders

一氧化氮化糖原磷酸化酶调控核糖原分解,并在代谢性肝脏疾病中受损

2026-10-020
OAAI
Identification of alterations of immunometabolism associated with Pompe disease

鉴定与Pompe病相关的免疫代谢改变

2026-03-160
OAAI
A myotropic AAV vector combined with skeletal muscle cis-regulatory elements improve glycogen clearance in mouse models of Pompe disease

一种肌动性AAV载体与骨骼肌顺式调控元件相结合,可改善庞贝病小鼠模型的糖原清除。

2025-06-010
OAAI
AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain

AAV载体在人iPSC来源的中枢神经系统模型和鼠脑中触发依赖DNA损伤反应的促炎信号。

2025-04-180
OA
Rescue of lysosomal acid lipase deficiency in mice by rAAV8 liver gene transfer

通过rAAV8肝脏基因转移对小鼠溶酶体酸性脂肪酶缺乏症的救治

2025-04-110
OA
Synergism of dual AAV gene therapy and rapamycin rescues GSDIII phenotype in muscle and liver
2024-05-161
OAAI
A functional mini-GDE transgene corrects impairment in models of glycogen storage disease type III
2024-01-162
OAAI
Gene Therapy in Patients with the Crigler-Najjar Syndrome

Crigler-najjar综合征患者的基因治疗

2023-08-1726
PRE
LSD1/PRMT6-targeting gene therapy to attenuate androgen receptor toxic gain-of-function ameliorates spinobulbar muscular atrophy phenotypes in flies and mice
2023-02-0613
OAAI
Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders
2022-09-2331
OAAI
Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques
2022-09-018
OAAI